Pemetrexed for the treatment of non-small-cell lung cancer

TA124 Lung cancer (non-small-cell) - pemetrexed: review decision - May 2012 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 148 KB)

Lung cancer (non-small-cell) - pemetrexed: review proposal - July 2011 information

Appendix A: provisional matrix of stakeholders (PDF 65 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 168 KB)

Review Decision - March 2010 information

Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 88 KB)

Review Proposal - August 2009 information

A full list of the organisations contacted for this review (PDF 32 KB)

Proposal paper considered by the Institute's Guidance Executive (PDF 150 KB)

TA124 Lung cancer (non-small cell) - pemetrexed: distribution list (PDF 18 KB)

NICE issues guidance on pemetrexed (Alimta) for the treatment of non-small-cell lung cancer information

NICE issues guidance on pemetrexed (Alimta) for the treatment of non-small-cell lung cancer (PDF 34 KB)

Eli Lilly and Company Limited

Appeals received (PDF 56 KB)

Initial scrutiny letter (PDF 17 KB)

Eli Lilly response to scrutiny letter (PDF 25 KB)

Final scrutiny letter (PDF 17 KB)

Lung cancer (non-small cell) - pemetrexed: Result of appeal (PDF 43 KB)

Appeal  information

Appeal announcement information

Lung cancer (non-small cell) - pemetrexed: final appraisal determination information

Evidence considered

Manufacturer submission

Manufacturer submission (PDF 2.72 MB)

Clarification response from manufacturer (PDF 194 KB)

Expert written personal statements

Baird (PDF 47 KB)

Ferry (PDF 58 KB)

O'Brien (PDF 27 KB)

Sawicka (PDF 37 KB)

Pre meeting brief (PDF 69 KB)

Lung cancer (non-small-cell) - pemetrexed: evidence review group report (PDF 540 KB)

Evidence review group report - additional analysis (PDF 42 KB)

Final matrix (PDF 33 KB)

Elizabeth Sawicka (PDF 18 KB)

Consultee and Commentator comments on the appraisal consultation document

Cancerbackup (PDF 44 KB)

Cancer Network Pharmacists forum (PDF 18 KB)

Department of Health (PDF 30 KB)

Eli Lilly and Company Ltd (PDF 112 KB)

Royal College of Nursing (PDF 25 KB)

Royal College of Physicians, the Royal College of Radiologists, the Association of Cancer Physicians, the Joint Collegiate Council for Oncology, and the National Cancer Research Institute Lung Cancer Group (PDF 30 KB)

Roy Castle Lung foundation (PDF 23 KB)

Sanofi Aventis (PDF 426 KB)

Lung cancer (non-small cell) - pemetrexed: final appraisal determination (PDF 73 KB)

summary table of Consultee and Commentator comments on the appraisal consultation document (PDF 187 KB)

summary table of web and public comments on the appraisal consultation document (PDF 31 KB)

Note on calculations performed at Committee Meeting (PDF 30 KB)

Pemetrexed for the treatment of non-small-cell lung cancer (appraisal consultation document) information